{"id":43270,"date":"2021-02-11T19:21:56","date_gmt":"2021-02-11T23:21:56","guid":{"rendered":"http:\/\/blogs.sld.cu\/marionod\/?p=43270"},"modified":"2021-02-11T19:25:37","modified_gmt":"2021-02-11T23:25:37","slug":"society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/marionod\/2021\/02\/11\/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma\/","title":{"rendered":"Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma"},"content":{"rendered":"<p><a href=\"https:\/\/jitc.bmj.com\/content\/5\/1\/68\" target=\"_blank\">Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma<\/a><\/p>\n<p>Art\u00edculo a texto completo publicado en la revista <a href=\"https:\/\/jitc.bmj.com\/\" target=\"_blank\">Journal of Immunotherapy of Cancer<\/a> La norma de atenci\u00f3n para la mayor\u00eda de los pacientes con c\u00e1ncer de vejiga no invasivo muscular (NMIBC) es la inmunoterapia con Bacillus Calmette-Gu\u00e9rin (BCG), que activa el sistema inmunitario para reconocer y destruir las c\u00e9lulas malignas y ha demostrado un beneficio cl\u00ednico duradero. La <a href=\"https:\/\/www.sitcancer.org\/\" target=\"_blank\">Sociedad para la Inmunoterapia del C\u00e1ncer<\/a> ha publicado esta declaraci\u00f3n de consenso\u00a0 sobre inmunoterapia para el tratamiento del carcinoma vesical. Esta gu\u00eda ayudar\u00e1 a los onc\u00f3logos en la toma de decisiones cl\u00ednicas efectivas en relaci\u00f3n con la selecci\u00f3n del paciente, el manejo de la toxicidad, la evaluaci\u00f3n de la respuesta y la secuenciaci\u00f3n o combinaci\u00f3n de terapias, y problemas de calidad de vida del paciente. Idioma: ingl\u00e9s<br \/>\n<cite class=\"highwire-cite highwire-cite-highwire-article highwire-citation-bmjj-title clearfix\"><\/cite><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma Art\u00edculo a texto completo publicado en la revista Journal of Immunotherapy of Cancer La norma de atenci\u00f3n para la mayor\u00eda de los pacientes con c\u00e1ncer de vejiga no invasivo muscular (NMIBC) es la inmunoterapia con Bacillus Calmette-Gu\u00e9rin (BCG), que activa [&hellip;]<\/p>\n","protected":false},"author":126,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[117,66,152,1757,485,22,4,116,1335],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/43270"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/users\/126"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/comments?post=43270"}],"version-history":[{"count":3,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/43270\/revisions"}],"predecessor-version":[{"id":43273,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/posts\/43270\/revisions\/43273"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/media?parent=43270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/categories?post=43270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/marionod\/wp-json\/wp\/v2\/tags?post=43270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}